VYTERIS INC (fka VYTRQ)

[Renee]

VYTRQ revoked:

http://www.sec.gov/litigation/admin/2014/34-71996.pdf

[Renee]

VYTRQ SEC Suspension:

http://www.sec.gov/litigation/suspensions/2014/34-71578.pdf

Order:

http://www.sec.gov/litigation/suspensions/2014/34-71578-o.pdf

Admin Proceeding:

http://www.sec.gov/litigation/admin/2014/34-71579.pdf

[Teamlasvegas]

VYHN
1.25 @ 3.00
V = 0

[Teamlasvegas]

June 17, 2008 - 1:02 PM EDT

VYTR 0.15 0.00

Vyteris, Inc. Announces Completion of Reverse Stock Split and New Trading Symbol
Steps Part of Implementation of Strategic Vision

Vyteris, Inc. (OTCBB: VYTR), manufacturer of the first FDA-approved active patch transdermal drug delivery system, announced implementation of a 1 for 15 reverse split of the company’s common stock, as well as the designation of a new trading symbol by NASDAQ.

The reverse stock split affects all of the company’s common stock, stock options, Series B Preferred Stock and warrants outstanding immediately prior to the effective date of the reverse stock split. The reverse split will reduce Vyteris, Inc. common stock outstanding from approximately 107,959,312 shares to approximately 7,197,287 shares and the number of authorized shares of common stock has been reduced from 500,000,000 shares to 33,333,333 shares.

“This marks another step in our previously announced plans for restructuring the company’s operations and placing the company in a stronger financial position to pursue its strategic plans,” said Joseph Himy, chief financial officer for Vyteris, Inc. “We will continue to focus our efforts on managing resources to become more effective in pursuing joint drug development partnerships in the areas of peptide and biopharmaceutical drug delivery using our proprietary transdermal delivery technology.”

Effective June 17, 2008, Vyteris, Inc. will begin trading on a split-adjusted basis under the common stock symbol “VYTR.”

About Vyteris, Inc.

Vyteris, Inc., a wholly owned subsidiary of Vyteris Holdings (Nevada), Inc. (OTCBB: VYHN), is the maker of the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris’ proprietary active transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that may result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. For more information, please visit our website at www.vyteris.com.

Vyteris Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the safe harbor provisions of the United States Private Securities Litigation Reform Act of 1995. Words such as “expect,” “estimate,” “project,” “anticipate,” “intend,” “plan,” “may,” “will,” “could,” “would,” “should,” “believes,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements in this press release include, without limitation, statements concerning the potential impact of the new marketing agreement and other matters that involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to differ materially from results expressed or implied by this press release. Such risk factors include, among others, the competitive environment and competitive responses to the new marketing arrangement. The Company has described other important risks and uncertainties under the caption "Risk Factors" in its most recent Annual Report on Form 10-KSB and in various filings made with the SEC. Actual results may differ materially from those contained in the forward-looking statements in this press release.

To receive regular email updates, please click

(http://www.vyteris.com/home/Contact_Us/index.php)



The Lee Strategy Group, Inc.
James Lee, 310-229-5771
[e-mail]



Source: Business Wire (June 17, 2008 - 1:02 PM EDT)

News by QuoteMedia
www.quotemedia.com

[alien42]

what a play that would have been, VYHN up near 90% today.

[stock_me_up]

woooooo nelly.... 14 cent 52...week...low

glad I did not buy in last year during the pump up to 3 bucks, watching for a possible bounce play however I doubt I will have the nerve to play.

[stock_me_up]

Ouch..... down 90% since I started watching this stock, when will it end?

[alien42]

still watching, VYHN at .20 and down 30% today.

[alien42]

still watching, may start nibbling

[alien42]

VYHN stabile at .30 for the past couple of weeks

[stock_me_up]

wow I just noticed the pop in the pps from friday, too bad it did not follow through today. Looking for better times ahead, glta

[max2205]

yes, with the huge blocks I saw going through I am sure news will come soon. Good or bad.. Got a lotto on this now

[alien42]

this is quite the situation...

VYHN is up 72% on VERY heavy volume after reaching 52 weeks lows

looks like they already have FDA approval for a product with amazing potential

this is definately worth looking into further...

[stock_me_up]

LidoSite(R) Now Available to Patients in Physician Offices
Monday August 13, 9:00 am ET
Physician Offices Can Begin Ordering LidoSite At 888-VYTERIS


FAIR LAWN, N.J.--(BUSINESS WIRE)--Marking an advance in the widespread distribution of rapid pain relief from procedures involving venipuncture, intravenous cannulation and laser ablation of superficial skin lesions, Vyteris, Inc. (OTCBB: VYHN - News) announced the commercial availability of LidoSite® to the 40 million American patients in physician offices who are needle averse or even phobic.

"This marks a significant step in the treatment of pain resulting from needles and laser ablation and provides physicians and patients a new and powerful tool in improving patient comfort," said Timothy J. McIntyre, president and chief executive officer for Vyteris, Inc. "As a fast-acting alternative to topical creams or simply trying to ignore needle pain, we believe LidoSite will be well-received by patients and physicians."

With close to one billion blood draws taken a year in the U.S., according to a study by market research firm TVG, it is estimated that each year approximately 40 million American patients experienced "high discomfort" with blood draws due to needle pain(1). An overwhelming majority of the surveyed patients who experienced "high discomfort" - 65 percent indicated they intended to use or ask for LidoSite at their next blood draw - representing an initial potential U.S. market for LidoSite of 26 million patients annually for this segment alone.

Working alongside its marketing partner in Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH - News) in the general practice physician market, Vyteris also announced the retention of experienced specialty sales representatives to make LidoSite broadly available in high demand specialties such as rheumatology, oncology and dermatology.

"Launching LidoSite into the U.S. physician office market represents a strategic and significant accomplishment for Vyteris by offering the first real, scalable product commercialization by the company on its own," McIntyre said. "This knocks down yet another important strategic benchmark outlined to our shareholders at the beginning of the year and is another important step in our three-year growth plan."

LidoSite is the first active transdermal patch approved by the U.S. Food and Drug Administration to deal with pain associated with blood draws (venipuncture) IV (intravenous) cannulations and laser ablation of superficial skin lesions. The device uses the process of iontophoresis to carry a combination of the local anesthetic lidocaine and vasoconstrictor epinephrine, which localizes the anesthetic effect, from a patch through the skin layer and into the underlying tissue by way of a mild electrical current.

LidoSite is composed of a heart-shaped controller that houses a microprocessor regulating dosing of medication, intervals and duration of dosing and is good for up to 99 patch applications.

The use of LidoSite is supported by the Blue Cross/Blue Shield Technical Evaluation Center (TEC), which indicated that "use of iontophoresis to administer local anesthetic before skin puncture or dermal procedures meets the TEC criteria." Various Blue Cross/Blue Shield health insurance plans have also previously issued medical practice guidelines supporting TEC findings and indicating that "iontophoresis is considered medically necessary to administer local anesthesia prior to a venipuncture or dermatological procedure." (2)

The American Pain Society (APS) and the American Academy of Pediatrics (AAP) set forth guidelines(3) for adequately addressing acute - or short-lived - pain. These guidelines, which apply to the treatment of children and adults, call for healthcare practitioners to eliminate or reduce pain caused by medical treatments whenever possible. In fact, the APS and AAP agree that acute pain experienced with medical procedures can, in most cases, be substantially reduced and even prevented

To find out more about LidoSite or to place an order if you are a physician, call 888-VYTERIS (898-3747) or visit us online at www.vyteris.com/lidosite.

[stock_me_up]

Vyteris, Inc. Announces Hiring of Specialty Sales and Marketing Team for Commercialization of LidoSite(R)
Wednesday August 8, 9:00 am ET
Physician Offices Can Begin Ordering LidoSite(R) At 888-VYTERIS


FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTCBB: VYHN - News) kicked off the nationwide commercial availability of its LidoSite® transdermal patch with the deployment of a specialty sales and marketing team dedicated to the promotion and sale of LidoSite into targeted physician specialty offices, including rheumatologists, oncologists, and dermatologists.

LidoSite provides patients with rapid pain relief from procedures involving venipuncture, intravenous cannulation and laser ablation of superficial skin lesions. To head up the sales and marketing efforts, the hiring of Eric Pluckhorn as senior vice president of sales and marketing was also announced.

"The retention of an experienced pharmaceutical and medical device sales force marks our nationwide launch into the highly lucrative physician office market for LidoSite," said Timothy J. McIntyre, president and chief executive officer for Vyteris, Inc. "We believe the market for LidoSite is robust with patients, physicians and nurses looking for an effective alternative to topical cream anesthetics and distraction techniques to avoid pain associated with venipuncture/needle pain."

With more than one billion blood draws taken a year in the U.S.,(1) a recent study by market research firm TVG, Inc. found that approximately 40 million patients a year experience "high discomfort" with blood draws due to needle pain.(2)

An overwhelming majority of the surveyed patients who experienced "high discomfort" - 65 percent in this case - indicated they intended to use or ask for LidoSite at their next blood draw; a potential U.S. market for LidoSite of 26 million patients annually.

The new specialty sales and marketing team will include specialty sales representatives and management positions to support physicians and their staffs in training on LidoSite, and in-service specialists. This exclusive team will work alongside Laboratory Corporation of America® Holdings (LabCorp®) (NYSE:LH - News), Vyteris' marketing partner in the general practice physician office market.

"I look forward to the opportunity to guide the sales growth and adoption of LidoSite into physician offices where we believe it can become a preferred treatment prior to cannulation procedures such as blood draws, venipuncture, IV catheter insertions or use prior to superficial dermatological procedures," Pluckhorn said. "We have assembled a talented and strong sales team of experienced professionals who are eager to implement our marketing effort."

In another recent clinical study by INC Research(3), more than half of rheumatology physicians surveyed found LidoSite exceeded their expectations with regard to positively impacting their patient's experience. Overall, the majority of physicians in the study were satisfied with the LidoSite Topical System in its ease of use and conformity to standard office practices for rheumatology treatment applications.

LidoSite is the first active transdermal patch approved by the U.S. Food and Drug Administration to deal with pain associated with venipuncture for injections, intravenous cannulation for blood draws and laser ablation of superficial skin lesions. The device uses the process of iontophoresis to carry a combination of the pain killer lidocaine and epinephrine, which localizes the anesthetic effect, from a patch through the skin layer and into the underlying tissue by way of a mild electrical current.

LidoSite is composed of a heart-shaped controller housing a microprocessor regulating dosing of medication, intervals and duration of dosing and is good for up to 99 patch applications. Physicians interested in ordering LidoSite or receiving more information, can call 888-VYTERIS (898-3747) or go to www.vyteris.com/lidosite.

[stock_me_up]

Vyteris Announces Appointment of Anthony J. Cherichella as Chief Financial Officer
Thursday August 2, 9:00 am ET
Hiring Reflects Strengthening of Financial and Investor Relations Programs


FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTCBB: VYHN - News) announced today the appointment of Anthony J. Cherichella as chief financial officer and principal accounting officer, overseeing financing, forecasts and investor relations.

"Tony brings an enormous wealth of public healthcare company experience which will prove an integral part of our efforts in moving towards commercialization of our products," said Timothy J. McIntyre, president and chief executive officer of Vyteris. "A financial executive with his background strengthens our management team and delivers on our commitment enhance our relationship with present and future Vyteris shareholders and the investment community."

Most recently, Cherichella, 39, was the chief financial officer and acting president for Cardinal Health's Healthcare Marketing Services unit based in Wayne, NJ, a position he held from 2002 to the present. In that capacity, he had overall responsibility for establishing and managing financial budgets and forecasts, evaluating acquisitions and exploring strategic alternatives for this unit of Cardinal Health.

Prior to that, he served at BLP Group Companies from 2000-02, where he was chief financial officer, executive vice president, secretary and treasurer. Before that, he served as a senior audit manager for Andersen LLP from 1990-2000.

"I am grateful for the opportunity to come in at such an exciting time for Vyteris where we are poised to fully commit towards the commercialization and sale of LidoSite and provide pain relief for patients, and also future opportunities to increase value for our shareholders," Cherichella said. "This is a tremendous opportunity and one I look forward to."

Cherichella received his Bachelor of Science degree in Accounting from Fairleigh Dickinson University. He is a certified public accountant and a member of the American Institute of Certified Public Accountants. He serves on the Board of Trustees of Caldwell College of New Jersey as well as on its Finance Committee. He is married with two daughters.

[stock_me_up]

Vyteris Announces Successful Closing of Private Placement Raising $12.7 Million
Wednesday August 1, 9:36 am ET
Company Intends to Use Proceeds for Commercial Rollout of LidoSite(R)


FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris Inc. (OTCBB: VYHN - News) today announced the completion of a new private placement financing transaction in which it raised $12.7 million in cash, for net proceeds of $11.4 million after legal and transactions costs of $1.3 million. This follows another financing round last October 2006 for $23.1 million.

"This successful raise is another demonstration of continued investor confidence in our strategic plan, specifically the commercialization and rollout of our LidoSite active transdermal patch product into the U.S. physician office marketplace, where over two million blood draws are performed daily," said Timothy J. McIntyre, president and chief executive officer of Vyteris.

Use of proceeds from the financing are targeted for commercial rollout, including additions to the company's management expertise for commercialization, start up of a robust customer support system for the LabCorp partnership, initiation of the Vyteris specialty sales force, increase in manufacturing and product inventory for 2008, and supporting marketing and promotion activities for LidoSite, which will be available to the physician office market beginning the third quarter of 2007.

[stock_me_up]

Vyteris, Inc. Announces LidoSite(R) Marketing Agreement with LabCorp(R)
Monday June 11, 3:24 pm ET


FAIR LAWN, N.J.--(BUSINESS WIRE)--Vyteris, Inc. (OTCBB: VYHN - News) today announced an agreement granting Laboratory Corporation of America® Holdings (LabCorp®) (NYSE: LH - News), a national leader in clinical laboratory testing, rights to represent and offer Vyteris' LidoSite®, the first FDA-approved active transdermal smart patch for relief from pain associated with venipunctures and blood draws among certain patients. The agreement allows LabCorp to make LidoSite available for outpatient use to physician offices nationally.

"We are very pleased to have entered into this agreement with LabCorp, which has the infrastructure and track record of introducing new products to the market to improve patient care," said Timothy J. McIntyre, chief executive officer of Vyteris.

Vyteris' proprietary active transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows more precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that can result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration.

In conjunction with physician guidance, clinical laboratory testing remains one of the most cost-effective ways to help assess, diagnose, treat and monitor patient health. However, 20-25 percent of patients may be pain sensitive or needle phobic, which may interfere with compliance with physician orders for blood testing. LidoSite helps to remove this barrier and can lead to improved patient care and better health outcomes.

Under the terms of the agreement, LabCorp will be the only independent clinical laboratory in the U.S. offering LidoSite for outpatient use to physicians. Further details were not disclosed.

About Vyteris, Inc.

Vyteris, Inc., (OTCBB: VYHN - News), is the maker of the first active drug delivery patch to receive marketing clearance from the U.S. Food and Drug Administration (FDA). Vyteris' proprietary active transdermal drug delivery (iontophoresis) technology delivers drugs comfortably through the skin using low-level electrical energy. This active patch technology allows precise dosing, giving physicians and patients control in the rate, dosage and pattern of drug delivery that can result in considerable therapeutic, economical, and lifestyle advantages over existing methods of drug administration. Vyteris' first product, LidoSiteR, which provides dermal analgesia prior to venipuncture (IV catheter insertions, blood draws, etc.) and superficial dermatological procedures, was the first FDA approved active patch. Vyteris has also successfully demonstrated in-vivo, either in animals or in humans, the ability of their active patch technology to deliver drugs transdermally for the following applications: smoking cessation, anti-aging cosmeceuticals, treatments for Parkinson's disease, and peptides for various indications. For more information, please visit our website at www.vyteris.com